ABPI backs Darzi calls for greater innovation in NHS
The Association of the British Pharmaceutical Industry (ABPI) has welcomed new measures to improve access to modern medicines announced by Lord Darzi in his report into the NHS.
The Association of the British Pharmaceutical Industry (ABPI) has welcomed new measures to improve access to modern medicines announced by Lord Darzi in his report into the NHS.
Lord Darzi's "NHS Next Stage Review Final" Report states that innovation must be central to the NHS - a position that has been welcomed by the ABPI.
He addresses the problems of access to innovative technologies, and proposes solutions through streamlined technology appraisals and compulsory availability of approved treatments.
"In his review, Darzi returns to the problem of uptake of new technologies by the NHS, identified by Wanless in 2001," said Andy Taylor, ABHI policy director.
"In the intervening years improvement has been slow so this renewed focus on access is very welcome. Patients in the UK are often amongst the last to benefit from even UK-produced innovations and this clearly needs to be addressed. Patients must be empowered to demand the highest standards of service and quality, with all NICE approved treatments and technologies made available to all patients irrespective of postcode."
ABPI director general Dr Richard Barker said that the measures represented the basis for a huge leap forward in driving the use of best available treatment, including the uptake of NICE guidance, across the NHS.
"The task is now to deliver on the promise, so that people across the UK have full and fair access to innovative, life-extending medicines, demonstrated to be clinically-effective and cost-effective."
He added: "Britain's innovative pharmaceutical industry will also gain, by serving a more innovative customer, one that will also be a more attractive location for future clinical trials - a further benefit for UK patients."
Chris Brinsmead, president of the ABPI, said: "We welcome a series of measures that offer the opportunity to effect a seismic change in patients' right to access the best and most modern medicines based on clinical need. We look forward to working in partnership with Government and other stakeholders to ensure that this opportunity is realised."
